Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25688980 | 0.84 | PIK3CD (0.51) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17951262 | 0.83 | PIK3CA (0.57) | PIK3CABRAFMTORATMATR | |
| SCHEMBL742825 | 0.82 | PIK3CA (0.54) | PIK3CABRAFMTORATMATR | |
| SCHEMBL24589113 | 0.80 | PIK3CA (0.52) | PIK3CABRAFMTORATMATR | |
| SCHEMBL15651799 | 0.80 | PIK3CA (0.52) | PIK3CABRAFMTORATMATR | |
| SCHEMBL30902114 | 0.76 | PIK3CA (0.48) | PIK3CABRAFMTORATMATR | |
| SCHEMBL741557 | 0.76 | PIK3CA (0.48) | PIK3CABRAFMTORATMATR | |
| SCHEMBL8118119 | 0.76 | PIK3CA (0.48) | PIK3CABRAFMTORATMATR | |
| SCHEMBL15652311 | 0.74 | PIK3CA (0.47) | PIK3CABRAFMTORATMATR | |
| SCHEMBL789960 | 0.74 | ALPL (0.48) | PIK3CABRAFMTORATMATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, PIK3CB | PIK3CA 1/4885BRAF 15/4885MTOR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.